Exercise-induced Myocardial DamagePhase 4NCT06715748
Effects of Exogenous Ketones on Acute Changes and Recovery of the Heart Muscle After Intense Exercise.
A Phase 4 study testing Ketone Monoester (KE) in people with Exercise-induced Myocardial Damage and Right Ventricular Diastolic Dysfunction, run by Jessa Hospital at 1 site in Belgium.
Trial summary
It is well known that scar tissue on the heart muscle can cause (life-threatening) arrhythmias. However, the exact cause of this scar tissue is not entirely clear. It is possible that prolonged and intense exercise is associated with (limited) inflammation of the heart muscle, carrying the risk of scar tissue… Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Exercise-induced Myocardial Damage, Right Ventricular Diastolic Dysfunction
- What is being tested?
- Ketone Monoester (KE)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteBelgium
- Study dates
- 17 Oct 2024to 22 Dec 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy recreational male and female cyclists between 18 and 50 years old, who have signed an informed consent form.
- Participants will be included if they achieve a VO2-max/kg value above P90, corrected for age and sex, based on the reference value by E. Van der Steeg et al.
Who cannot join
- Cardiovascular, metabolic, or respiratory diseases
- Participants with cardiovascular risk factors
- Contraindications for maximum exercise
- Contraindications for MRI.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Jessa Hospital
Hasselt, Limburg, 3500
Benjamin Peters, MD, +32 11 55 55 55, benjamin.Peters@jessazh.be
About this study
Official title: Prospective Study Investigating the Effects of Intense Endurance Exercise on the Heart Muscle and the Effect of Exogenous Ketones on Acute Changes and Recovery of the Heart Muscle.
It is well known that scar tissue on the heart muscle can cause (life-threatening) arrhythmias. However, the exact cause of this scar tissue is not entirely clear. It is possible that prolonged and intense exercise is associated with (limited) inflammation of the heart muscle, carrying the risk of scar tissue development.
The aim of this project is to evaluate the impact of prolonged and intense exercise on the heart. Participants will be asked to cycle for a total of 3 hours, of which 2 hours will be at an intense pace. Approximately 30 recreational cyclists will be invited to participate in this research project. Specifically, the investigators want to examine whether prolonged and intense exercise is associated with inflammation of the heart muscle and whether it affects heart function recovery. The research project will take place in a laboratory setting, where heart rate, blood pressure, food and fluid intake, and exertion level will be monitored. Before, after and 20-24h after the intense exercise, a lab test and extensive heart imaging will be performed using magnetic resonance imaging (MRI) and cardiac ultrasound. The investigators aim to study the effect of ketone intake (a dietary supplement that may enhance performance or recovery) on recovery. For this, a double blind cross-over design will be setup. Participants will complete the same exercise twice, with a 1-3 week interval, once with a placebo and once with ketones. All the same baseline, post-exercise and recovery investigations will be perfromed.
Read more
In the second part of the study, the investigators will evaluate and compare various rhythm-monitoring devices, both during intense exercise and in daily life. For this, participants will be asked to wear each of four devices for one week in a home setting. These are very small devices that are not externally visible when worn under clothing.
Participation in this project will involve a various questionnaires and tests.
Read the detailed description
### BACKGROUND:
It has already been established that extensive exercise results in functional and biochemical myocardial damage. However, the development of exercise-induced myocardial edema remains unclear. Native T1 and T2 mapping techniques in cardiac magnetic resonance imaging (CMR) are sensitive to detecting pathological myocardial fluid accumulation and thus serve as potential biomarkers for identifying pathological myocardial edema. A pilot study conducted by Ghekiere et al. demonstrated a correlation between elevated troponin release and increased T1 mapping values, as well as right ventricular (RV) dysfunction. The objective of this study is to perform an additional study with 30 participants, using an adapted study protocol to overcome the main limitations of the pilot study and to evaluate the effects of exogeneous ketones on acute cardiac changes and recovery.
---
- OBJECTIVES
This research aims to investigate whether cardiac abnormalities develop following intense exercise and whether these abnormalities recover or persist after 20-24 hours. Specifically, the investigators will examine whether myocardial edema, cardiac dysfunction, or abnormalities in contractile reserve occur after intense exercise. The investigators intend to examine whether the use of ketones influences the occurrence and recovery of these cardiac abnormalities. A pilot study by Ghekiere et al. showed a correlation between exercise-induced troponin release and elevated T1 mapping values, along with RV dysfunction. The goal of this study is to further explore these findings in a larger population. The investigators will evaluate whether extensive exercise is associated with pathological levels of fluid accumulation in the myocardium, potentially indicating pathological myocardial edema. Additionally, the investigators will assess if ventricular dysfunction occurs and whether contractile reserve changes following intense exercise. Finally, the investigators will examine whether previous findings recover or remain 24 hours after intense exercise, as well as any potential differences between men and women, and the influence of intake of ketones. These findings could contribute to research on pathological heart damage and sudden death in professional cyclists and potentially shed light on the effects of ketones on recovery from cardiac injury.
- The investigators will evaluate whether intense endurance exercise affects the heart muscle.
- The investigators will evaluate whether any effects persist or disappear after 24 hours.
- The investigators will evaluate potential differences between placebo and ketone intake.
- The investigators will evaluate potential differences between male and female participants. ### STUDY POPULATION The inclusion criteria are healthy recreational male and female cyclists between 18 and 50 years old, who have signed an informed consent form. Female participants who take contraceptives will be included to prevent hormonal fluctuations from affecting the study results. Each participant will undergo a detailed questionnaire on their training history. Participants will be included if they achieve a VO2-max/kg value above P90, corrected for age and sex, based on the reference value by E. Van der Steeg et al. Exclusion criteria include cardiovascular, metabolic, or respiratory diseases, participants with cardiovascular risk factors, and any contraindications for maximum exercise or MRI. The investigators expect approximately 30 participants.
- RECRUITMENT AND INFORMED CONSENT Participants will be recruited from the personal networks of the research team as well as through local sports clubs. No pressure will be applied on potential participants. Participation is voluntary, and individuals have the right to decline participation or withdraw at any time without providing a reason, without affecting their relationship with the researcher. Local sports clubs will be contacted via email and social media. Participants will receive study information via email and can ask questions about the study at any time by email or phone. The study will be explained again at baseline, and the informed consent will then be offered for signing. Informed consent will be collected by the research team. Separate forms will be provided for the study-specific procedures, clarifying that the study falls outside standard care, so no billing will occur. --- ### METHODOLOGY This is an interventional prospective crossover study. Participants will be recruited through acquaintances and local sports clubs. All participants will receive information and a questionnaire and must sign an informed consent. All participants will undergo an VO2-max test before the intense exercise to calculate aerobic and anaerobic thresholds, including VO2 max. Prior to the intense exercise, a baseline CMR study will be performed at rest with T1 mapping and T2 mapping (SA basal and midventricular and HLA), functional measurements (HLA, VLA, 3CH, and SA for both ventricles), stress measurements (Supine Exercise-CMR), and contrast-enhanced imaging to detect fibrosis. Baseline blood tests (Na, K, Ca, Chl, Mg, Creatinine, RBC + Hct, Hg, WBC, platelets, High sens Troponine I and T, Creatine kinase, Creatine kinase-MB, NT-proBNP, CRP, Estrogen, Testosterone, Lpa, NT-pro ANP, Albumine, Dopamine, GDF-15, serum B hydroxybutyrate, glucose, lactate, and urinalysis) will be taken to assess cardiac biomarkers and hydration status. A baseline Cardiac ultrasound will also be performed with ventricular function calculations and strain analysis. Participants will then undergo an extensive exercise session in controlled conditions (temperature and humidity) at a research lab, the Rehabilitation and Health Center (ReGo) of the Jessa Hospital. All participants will complete a standardized route using a ZWIFT setup, a virtual indoor training setup. The route lasts three hours and is individually adjusted based on the anaerobic threshold, aiming to maintain anaerobic exercise for 1.5-2.0 hours. During the test, a bicycle trainer (Wahoo Kickr) will be provided on which participants can mount their own bicycle. Food and fluid intake will be standardized. Heart rate and hydration balance will be monitored before, during and after the exercise. Glucose, lactate and beta-hydroxybutyrate serum levels will be monitored before, during and after the exercise on capillary blood samples. Heart rhythm will be continuously monitored before, during, and after exercise using several devices to compare and validate them in both clinical and home settings (devices: Fourth Frontier X2, Byteflies patch, Rooti Rx). All devices have CE marking, are very small and are not externally visible, and have been used in clinical situations. The monitoring setup will avoid disrupting daily activities. Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo (an isocaloric medium-chain triglyceride composition), separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. Three to six hours post-exercise, all participants will undergo Cardiac ultrasound, CMR examination with the same sequences as the baseline study, blood tests, and urinalysis. The same tests will be repeated 24 hours after baseline. Cardiac ultrasound evaluation will be performed by an experienced cardiologist. CMR post-processing will be conducted by two experienced cardiac radiologists, and rhythm monitoring will be assessed by an experienced cardiologist. Medical procedures will be performed by trained nursing staff and physicians according to usual clinical procedures. Rhythm monitoring data will be analyzed anonymously using company-provided software.
- RISK-BENEFIT BALANCE
- There is minimal risk associated with intense exercise. In rare cases, intense exertion can trigger arrhythmias. Previous studies have shown that sudden death occurs in about 1-2 cases per 100,000 athletes per year and 1 per 1 to 4 million hours of exercise. The investigators suspect the risk for our participants will be lower, as they will undergo cardiac evaluation before exercise, and the exercise will be conducted in a controlled setting. The controlled environment is likely to reduce the likelihood of serious complications, as potential issues can be identified and treated early.
- There is a small chance that the tests may reveal abnormalities that would otherwise remain unnoticed and pose no symptoms or danger. Such findings may cause unnecessary worry. If this occurs, the investigators will fully inform participants about the significance. Conversely, potentially early pathological findings with no symptoms may also be identified, allowing for timely assessment and treatment, potentially preventing or improving long-term outcomes.
- There is a very small risk of an allergic reaction to gadolinium contrast.
- DATA ANALYSIS Basic CMR post-processing will be performed on a commercial workstation used in routine clinical settings. Cine imaging of the heart will be segmented with commercially available software (NeoSOFT, USA). All study data will be pseudonymized. Left ventricular (LV) and right ventricular (RV) volumes will be outlined to calculate ejection fraction, end-diastolic volume, end-systolic volume, cardiac index, and cardiac mass. The thickness of the LV lateral wall and septum will be measured on SA and HLA images. Myocardial T1 and T2 relaxation times will be determined. Analyses will be conducted by two independent cardiac radiologists with expertise in cardiac imaging, blinded to all study data. Cardiac ultrasound will be performed and analysed by a cardiologists Raw ECG data will be made available via software provided by the respective companies (Byteflies, Fourth Frontier, and Rooti) and evaluated by an experience cardiologist. Statistical analysis will be conducted using IBM SPSS version 27.0 (IBM SPSS Statistics for Windows, Chicago, IL, USA). A Shapiro-Wilk test will be conducted to test the normal distribution of the data (p < 0.05).
- Being tested
- Ketone Monoester (KE), Placebo
- Keywords
- Exercise induced cardiac damage, Exogeneous ketone, Cardiac Recovery, CMR, Cardiac US, Troponine, Lpa, Exercise-CMR
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ketone Monoester (KE)Dietary supplement
Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-4 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
PlaceboDietary supplement
Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
| Study group | Role | What they receive |
|---|---|---|
| PLACEBO | Placebo comparator | Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. Receives: Dietary Supplement: Placebo |
| Keton | Active comparator | Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. Receives: Dietary Supplement: Ketone Monoester (KE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Troponin release after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo
Measured: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Change in contractile reserve measured with Exercise-CMR after identical streneous exercise will be significant different with Ketone ester supplementation compared to placebo.
Measured: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Secondary outcomes (3)
20-24h after indentical streneous exercise, recuperation of ventricular contractile reserve measured with Exercise-CMR will be significant different with Ketone ester supplementation compared to placebo.
Measured: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Change in T1-mapping values measured on CMR after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo
Measured: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Change in T2-mapping values measured on CMR after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo
Measured: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2024
- Study start17 Oct 2024
- Primary completion22 Dec 2026 (estimated)
- Study completion22 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Exercise-induced Myocardial DamageStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jessa Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06715748
- Sponsor's protocol ID
- B2432023000008
- Status last verified
- Nov 2024
- First submitted
- 18 Nov 2024
- Last updated
- 4 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected IPD
Publications
Ghekiere O, Herbots L, Peters B, Berg BV, Dresselaers T, Franssen W, Padovani B, Ducreux D, Ferrari E, Nchimi A, Demanez S, De Bosscher R, Willems R, Heidbuchel H, La Gerche A, Claessen G, Bogaert J, Eijnde BO. Exercise-induced myocardial T1 increase and right ventricular dysfunction in recreational cyclists: a CMR study. Eur J Appl Physiol. 2023 Oct;123(10):2107-2117. doi: 10.1007/s00421-023-05259-4. Epub 2023 Jul 22.
PubMed 37480391
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Study Investigating the Effects of Intense Endurance Exercise on the Heart Muscle and the Effect of Exogenous Ketones on Acute Changes and Recovery of the Heart Muscle.
- ClinicalTrials.gov ID
- NCT06715748
- Acronym / sponsor ID
- B2432023000008
- Keywords
- Exercise induced cardiac damage, Exogeneous ketone, Cardiac Recovery, CMR, Cardiac US, Troponine, Lpa, Exercise-CMR
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Jessa HospitalUniversity, hospital or other
- Study start
- 17 Oct 2024 (actual)
- Primary completion
- 22 Dec 2026 (estimated)
- Study completion
- 22 Dec 2026 (estimated)
- First posted
- 4 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is well known that scar tissue on the heart muscle can cause (life-threatening) arrhythmias. However, the exact cause of this scar tissue is not entirely clear. It is possible that prolonged and intense exercise is associated with (limited) inflammation of the heart muscle, carrying the risk of scar tissue development.
The aim of this project is to evaluate the impact of prolonged and intense exercise on the heart. Participants will be asked to cycle for a total of 3 hours, of which 2 hours will be at an intense pace. Approximately 30 recreational cyclists will be invited to participate in this research project. Specifically, the investigators want to examine whether prolonged and intense exercise is associated with inflammation of the heart muscle and whether it affects heart function recovery. The research project will take place in a laboratory setting, where heart rate, blood pressure, food and fluid intake, and exertion level will be monitored. Before, after and 20-24h after the intense exercise, a lab test and extensive heart imaging will be performed using magnetic resonance imaging (MRI) and cardiac ultrasound. The investigators aim to study the effect of ketone intake (a dietary supplement that may enhance performance or recovery) on recovery. For this, a double blind cross-over design will be setup. Participants will complete the same exercise twice, with a 1-3 week interval, once with a placebo and once with ketones. All the same baseline, post-exercise and recovery investigations will be perfromed.
In the second part of the study, the investigators will evaluate and compare various rhythm-monitoring devices, both during intense exercise and in daily life. For this, participants will be asked to wear each of four devices for one week in a home setting. These are very small devices that are not externally visible when worn under clothing.
Participation in this project will involve a various questionnaires and tests.
Detailed description
### BACKGROUND:
It has already been established that extensive exercise results in functional and biochemical myocardial damage. However, the development of exercise-induced myocardial edema remains unclear. Native T1 and T2 mapping techniques in cardiac magnetic resonance imaging (CMR) are sensitive to detecting pathological myocardial fluid accumulation and thus serve as potential biomarkers for identifying pathological myocardial edema. A pilot study conducted by Ghekiere et al. demonstrated a correlation between elevated troponin release and increased T1 mapping values, as well as right ventricular (RV) dysfunction. The objective of this study is to perform an additional study with 30 participants, using an adapted study protocol to overcome the main limitations of the pilot study and to evaluate the effects of exogeneous ketones on acute cardiac changes and recovery.
---
- OBJECTIVES
This research aims to investigate whether cardiac abnormalities develop following intense exercise and whether these abnormalities recover or persist after 20-24 hours. Specifically, the investigators will examine whether myocardial edema, cardiac dysfunction, or abnormalities in contractile reserve occur after intense exercise. The investigators intend to examine whether the use of ketones influences the occurrence and recovery of these cardiac abnormalities. A pilot study by Ghekiere et al. showed a correlation between exercise-induced troponin release and elevated T1 mapping values, along with RV dysfunction. The goal of this study is to further explore these findings in a larger population. The investigators will evaluate whether extensive exercise is associated with pathological levels of fluid accumulation in the myocardium, potentially indicating pathological myocardial edema. Additionally, the investigators will assess if ventricular dysfunction occurs and whether contractile reserve changes following intense exercise. Finally, the investigators will examine whether previous findings recover or remain 24 hours after intense exercise, as well as any potential differences between men and women, and the influence of intake of ketones. These findings could contribute to research on pathological heart damage and sudden death in professional cyclists and potentially shed light on the effects of ketones on recovery from cardiac injury.
- The investigators will evaluate whether intense endurance exercise affects the heart muscle.
- The investigators will evaluate whether any effects persist or disappear after 24 hours.
- The investigators will evaluate potential differences between placebo and ketone intake.
- The investigators will evaluate potential differences between male and female participants. ### STUDY POPULATION The inclusion criteria are healthy recreational male and female cyclists between 18 and 50 years old, who have signed an informed consent form. Female participants who take contraceptives will be included to prevent hormonal fluctuations from affecting the study results. Each participant will undergo a detailed questionnaire on their training history. Participants will be included if they achieve a VO2-max/kg value above P90, corrected for age and sex, based on the reference value by E. Van der Steeg et al. Exclusion criteria include cardiovascular, metabolic, or respiratory diseases, participants with cardiovascular risk factors, and any contraindications for maximum exercise or MRI. The investigators expect approximately 30 participants.
- RECRUITMENT AND INFORMED CONSENT Participants will be recruited from the personal networks of the research team as well as through local sports clubs. No pressure will be applied on potential participants. Participation is voluntary, and individuals have the right to decline participation or withdraw at any time without providing a reason, without affecting their relationship with the researcher. Local sports clubs will be contacted via email and social media. Participants will receive study information via email and can ask questions about the study at any time by email or phone. The study will be explained again at baseline, and the informed consent will then be offered for signing. Informed consent will be collected by the research team. Separate forms will be provided for the study-specific procedures, clarifying that the study falls outside standard care, so no billing will occur. --- ### METHODOLOGY This is an interventional prospective crossover study. Participants will be recruited through acquaintances and local sports clubs. All participants will receive information and a questionnaire and must sign an informed consent. All participants will undergo an VO2-max test before the intense exercise to calculate aerobic and anaerobic thresholds, including VO2 max. Prior to the intense exercise, a baseline CMR study will be performed at rest with T1 mapping and T2 mapping (SA basal and midventricular and HLA), functional measurements (HLA, VLA, 3CH, and SA for both ventricles), stress measurements (Supine Exercise-CMR), and contrast-enhanced imaging to detect fibrosis. Baseline blood tests (Na, K, Ca, Chl, Mg, Creatinine, RBC + Hct, Hg, WBC, platelets, High sens Troponine I and T, Creatine kinase, Creatine kinase-MB, NT-proBNP, CRP, Estrogen, Testosterone, Lpa, NT-pro ANP, Albumine, Dopamine, GDF-15, serum B hydroxybutyrate, glucose, lactate, and urinalysis) will be taken to assess cardiac biomarkers and hydration status. A baseline Cardiac ultrasound will also be performed with ventricular function calculations and strain analysis. Participants will then undergo an extensive exercise session in controlled conditions (temperature and humidity) at a research lab, the Rehabilitation and Health Center (ReGo) of the Jessa Hospital. All participants will complete a standardized route using a ZWIFT setup, a virtual indoor training setup. The route lasts three hours and is individually adjusted based on the anaerobic threshold, aiming to maintain anaerobic exercise for 1.5-2.0 hours. During the test, a bicycle trainer (Wahoo Kickr) will be provided on which participants can mount their own bicycle. Food and fluid intake will be standardized. Heart rate and hydration balance will be monitored before, during and after the exercise. Glucose, lactate and beta-hydroxybutyrate serum levels will be monitored before, during and after the exercise on capillary blood samples. Heart rhythm will be continuously monitored before, during, and after exercise using several devices to compare and validate them in both clinical and home settings (devices: Fourth Frontier X2, Byteflies patch, Rooti Rx). All devices have CE marking, are very small and are not externally visible, and have been used in clinical situations. The monitoring setup will avoid disrupting daily activities. Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo (an isocaloric medium-chain triglyceride composition), separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. Three to six hours post-exercise, all participants will undergo Cardiac ultrasound, CMR examination with the same sequences as the baseline study, blood tests, and urinalysis. The same tests will be repeated 24 hours after baseline. Cardiac ultrasound evaluation will be performed by an experienced cardiologist. CMR post-processing will be conducted by two experienced cardiac radiologists, and rhythm monitoring will be assessed by an experienced cardiologist. Medical procedures will be performed by trained nursing staff and physicians according to usual clinical procedures. Rhythm monitoring data will be analyzed anonymously using company-provided software.
- RISK-BENEFIT BALANCE
- There is minimal risk associated with intense exercise. In rare cases, intense exertion can trigger arrhythmias. Previous studies have shown that sudden death occurs in about 1-2 cases per 100,000 athletes per year and 1 per 1 to 4 million hours of exercise. The investigators suspect the risk for our participants will be lower, as they will undergo cardiac evaluation before exercise, and the exercise will be conducted in a controlled setting. The controlled environment is likely to reduce the likelihood of serious complications, as potential issues can be identified and treated early.
- There is a small chance that the tests may reveal abnormalities that would otherwise remain unnoticed and pose no symptoms or danger. Such findings may cause unnecessary worry. If this occurs, the investigators will fully inform participants about the significance. Conversely, potentially early pathological findings with no symptoms may also be identified, allowing for timely assessment and treatment, potentially preventing or improving long-term outcomes.
- There is a very small risk of an allergic reaction to gadolinium contrast.
- DATA ANALYSIS Basic CMR post-processing will be performed on a commercial workstation used in routine clinical settings. Cine imaging of the heart will be segmented with commercially available software (NeoSOFT, USA). All study data will be pseudonymized. Left ventricular (LV) and right ventricular (RV) volumes will be outlined to calculate ejection fraction, end-diastolic volume, end-systolic volume, cardiac index, and cardiac mass. The thickness of the LV lateral wall and septum will be measured on SA and HLA images. Myocardial T1 and T2 relaxation times will be determined. Analyses will be conducted by two independent cardiac radiologists with expertise in cardiac imaging, blinded to all study data. Cardiac ultrasound will be performed and analysed by a cardiologists Raw ECG data will be made available via software provided by the respective companies (Byteflies, Fourth Frontier, and Rooti) and evaluated by an experience cardiologist. Statistical analysis will be conducted using IBM SPSS version 27.0 (IBM SPSS Statistics for Windows, Chicago, IL, USA). A Shapiro-Wilk test will be conducted to test the normal distribution of the data (p < 0.05).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PLACEBO | Placebo comparator | Dietary Supplement: PlaceboParticipants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. |
| Keton | Active comparator | Dietary Supplement: Ketone Monoester (KE)Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- healthy recreational male and female cyclists between 18 and 50 years old, who have signed an informed consent form.
- Participants will be included if they achieve a VO2-max/kg value above P90, corrected for age and sex, based on the reference value by E. Van der Steeg et al.
Key exclusion criteria (4 listed)
- Cardiovascular, metabolic, or respiratory diseases
- Participants with cardiovascular risk factors
- Contraindications for maximum exercise
- Contraindications for MRI.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketone Monoester (KE)Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-4 weeks. Ketones and placebo will be orally administered according to a fixed schedule. | Dietary supplement | Keton |
| PlaceboParticipants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule. | Dietary supplement | PLACEBO |
Primary outcome
Troponin release after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo
Time frame: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Change in contractile reserve measured with Exercise-CMR after identical streneous exercise will be significant different with Ketone ester supplementation compared to placebo.
Time frame: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
3 secondary outcomes
20-24h after indentical streneous exercise, recuperation of ventricular contractile reserve measured with Exercise-CMR will be significant different with Ketone ester supplementation compared to placebo.
Time frame: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Change in T1-mapping values measured on CMR after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo
Time frame: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Change in T2-mapping values measured on CMR after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo
Time frame: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2024.
- Background: PubMed 37480391Ghekiere O, Herbots L, Peters B, Berg BV, Dresselaers T, Franssen W, Padovani B, Ducreux D, Ferrari E, Nchimi A, Demanez S, De Bosscher R, Willems R, Heidbuchel H, La Gerche A, Claessen G, Bogaert J, Eijnde BO. Exercise-induced myocardial T1 increase and right ventricular dysfunction in recreational cyclists: a CMR study. Eur J Appl Physiol. 2023 Oct;123(10):2107-2117. doi: 10.1007/s00421-023-05259-4. Epub 2023 Jul 22.
- Individual participant dataSharing planned: Yes. All collected IPD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ketone Monoester (KE) in people with Exercise-induced Myocardial Damage and Right Ventricular Diastolic Dysfunction, run by Jessa Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Benjamin Peters, MD (+32 11 33 55 55, benjamin.peters@jessazh.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Troponin release after identical strenuous exercise is significant different with Ketone ester supplementation compared to Placebo (time frame: All participants will do two identical streneous exercise within two weeks, day 1 with intake of Keton ester and day 2 with intake of Placebo. All participants will recieve baseline, post race and 20-24 hours post baseline investigations.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06715748, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2024.